Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of helium and sevoflurane is used in anesthesia, particularly for patients with upper airway obstruction. Helium is an inert gas that, when mixed with oxygen as a carrier gas for sevoflurane (a volatile anesthetic agent), can improve gas exchange and reduce airway resistance during anesthesia. ## Medical Applications Helium-sevoflurane combinations are particularly beneficial in: 1. Anesthesia for upper airway obstruction 2. Improving gas exchange during spontaneous ventilation 3. Reducing respiratory effort in patients with compromised airways Studies have shown that helium has negligible effects on the output of sevoflurane vaporizers, making it a safe carrier gas alternative to standard oxygen or air mixtures[1][4]. The presence of helium in the carrier gas does not adversely affect the performance of sevoflurane vaporizers, with changes in output remaining within ±10% of baseline even with varying carrier gas flow rates[1]. ## Physiological Benefits When helium is used with sevoflurane anesthesia: - It decreases audible inspiratory stridor - Improves gas exchange - Decreases respiratory rate - Reduces suprasternal/intercostal retractions - Decreases transcutaneous CO₂ levels[2] These benefits stem from helium's physical properties - it has lower density and viscosity compared to oxygen or air, which reduces the work of breathing through narrowed airways[8][9]. ## Safety Profile Helium is categorized as a "non-immobilizer" - a gas that does not induce anesthesia but may have other biological effects[8]. Unlike other noble gases such as xenon, helium lacks anesthetic properties and has no significant hemodynamic side effects, making it suitable for use in patients with respiratory difficulties during anesthesia[6][8]. The combination of helium and sevoflurane has been tested in clinical settings and found to be safe for use with standard vaporizers like Blease Datum and Drager Vapor 19.3[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Helium and Sevoflurane.